1513682-06-8

Basic information

• Product Name: N-(4-methoxy-2-methylphenyl)-3-nitropyridin-4-amine
• Synonyms: N-(4-methoxy-2-methylphenyl)-3-nitropyridin-4-amine
• CAS NO: 1513682-06-8
• Molecular Weight: 259.265
• Mol File: 1513682-06-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-methoxy-2-methylphenyl)-3-nitropyridin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-methoxy-2-methylphenyl)-3-nitropyridin-4-amine(1513682-06-8)
• EPA Substance Registry System: N-(4-methoxy-2-methylphenyl)-3-nitropyridin-4-amine(1513682-06-8)

Safety Data

• Hazardous Substances Data: 1513682-06-8(Hazardous Substances Data)

Upstream product

• 13091-23-1 4-chloro-3-nitropyridine 
• 102-50-1 2-methyl-4-methoxyaniline 

Downstream Products

• 1281263-35-1 N⁴-(4-methoxy-2-methylphenyl)pyridine-3,4-diamine 
• 1609259-89-3 1-(4-methoxy-2-methylphenyl)-2-methyl-1H-imidazo[4,5-c]pyridine 
• 1609259-88-2 3-methyl-4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenol 

Relevant articles and documents

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization

The discovery of D1 subtype-selective agonists with drug-like properties has been an enduring challenge for the greater part of 40 years. All known D1-selective agonists are catecholamines that bring about receptor desensitization and undergo rapid metabolism, thus limiting their utility as a therapeutic for chronic illness such as schizophrenia and Parkinson's disease. Our high-throughput screening efforts on D1 yielded a single non-catecholamine hit PF-4211 (6) that was developed into a series of potent D1 receptor agonist leads with high oral bioavailability and CNS penetration. An important structural feature of this series is the locked biaryl ring system resulting in atropisomerism. Disclosed herein is a summary of our hit-to-lead efforts on this series of D1 activators culminating in the discovery of atropisomer 31 (PF-06256142), a potent and selective orthosteric agonist of the D1 receptor that has reduced receptor desensitization relative to dopamine and other catechol-containing agonists.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.